文献速递泌尿男性生殖肿瘤

奥拉单抗联合米托蒽醌/泼尼松对比单用米托蒽醌/泼尼松二线治疗转移性去势抵抗性前列腺癌的随机II期研究

Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2018-12-17

这项随机II期研究纳入123例多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者,比较奥拉单抗联合米托蒽醌/泼尼松与单用米托蒽醌/泼尼松的疗效和安全性。主要终点无进展生存期两组无显著差异(HR=1.29,95%CI 0.87-1.90),总生存期亦无显著差异(HR=1.08,95%CI 0.72-1.61)。联合治疗安全性可接受,但未改善化疗疗效。

要点

  • 奥拉单抗联合米托蒽醌/泼尼松未显著改善无进展生存期(HR=1.29,95%CI 0.87-1.90)。
  • 总生存期两组无显著差异(HR=1.08,95%CI 0.72-1.61)。
  • 细胞计数>37个/7.5ml患者中联合组总生存期改善(交互P=0.043)。

核心结论

  • 奥拉单抗联合米托蒽醌/泼尼松安全性可接受,但未改善米托蒽醌/泼尼松化疗的疗效。
  • 作者认为可考虑在选定患者人群和更早期疾病阶段进一步研究。

研究设计与样本

  • 随机II期研究,纳入123例多西他赛治疗后进展的转移性去势抵抗性前列腺癌患者,随机分至奥拉单抗+米托蒽醌/泼尼松组63例或米托蒽醌/泼尼松组60例。
  • 奥拉单抗15 mg/kg,第1天和第8天给药;米托蒽醌12 mg/m2,第1天给药;泼尼松5 mg每日两次;21天为一周期。
  • 主要终点为无进展生存期,次要终点包括总生存期、安全性和循环肿瘤细胞计数。

主要发现

  • 中位无进展生存期奥拉单抗+米托蒽醌/泼尼松组为2.3个月,米托蒽醌/泼尼松组为2.4个月(HR=1.29;95%CI 0.87-1.90)。
  • 中位总生存期奥拉单抗+米托蒽醌/泼尼松组为14.2个月,米托蒽醌/泼尼松组为12.8个月(HR=1.08;95%CI 0.72-1.61)。
  • 两组毒性特征相似,最常见≥3级不良事件为中性粒细胞减少(奥拉单抗+米托蒽醌/泼尼松组24% vs 米托蒽醌/泼尼松组15%)、贫血(13% vs 14%)和疲乏(11% vs 9%)。
  • 高循环肿瘤细胞计数与两组较差的总生存期相关。
  • 细胞计数>37个/7.5ml的患者中,奥拉单抗+米托蒽醌/泼尼松组总生存期改善(交互P=0.043)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Platelet-derived growth factor receptor-α (PDGFRα) is expressed in primary prostate adenocarcinoma and in associated skeletal metastases. Olaratumab is a fully human monoclonal antibody that binds PDGFRα and blocks downstream signalling. This phase II study assessed the efficacy and safety of olaratumab in combination with mitoxantrone and prednisone (M/P) versus M/P alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after docetaxel. METHODS: Patients were randomised to receive 21-d cycles of olaratumab (15 mg/kg, Days 1 and 8) plus mitoxantrone (12 mg/m2, Day 1) and prednisone (5 mg, twice daily) or M/P alone. Progression-free survival (PFS) was the primary end-point. Secondary end-points included overall survival (OS), safety, and circulating tumour cell (CTC) counts. RESULTS: A total of 123 patients were randomised, 63 to olaratumab + M/P and 60 to M/P. Median PFS was 2.3 months for olaratumab + M/P and 2.4 months for M/P (hazard ratio [HR] = 1.29; 95% confidence interval [CI] = 0.87-1.90). Median OS was 14.2 months for olaratumab + M/P and 12.8 months for M/P (HR = 1.08; 95% CI = 0.72-1.61). Both treatment arms had similar toxicity profiles; neutropenia (24% versus 15%), anaemia (13% versus 14%) and fatigue (11% versus 9%) (olaratumab + M/P versus M/P, respectively) were the most common grade ≥3 events. High CTC count was associated with poorer OS in both arms. Patients with very high cell counts (>37 cells/7.5 ml) exhibited improved OS with olaratumab + M/P (interaction P = 0.043). CONCLUSIONS: Olaratumab + M/P had an acceptable safety profile but did not improve the efficacy of M/P chemotherapy. Further study with selected patient populations and earlier in the disease course might be considered.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hakenberg OW, Perez-Gracia JL, Castellano D, et al. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2018. PMID: 30573277. doi:10.1016/j.ejca.2018.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。